A naukri.com initiative
Bioengineer
1w
46
Image Credit: Bioengineer
Study Reveals Dietary Supplement May Alleviate Liver Cancer Severity Linked to Bile Acids
- Researchers at the Salk Institute have discovered that certain bile acids can severely impair the activity of T cells, which are components of the immune system tasked with identifying and eliminating cancer cells
- The study showed that blocking the synthesis of these bile acids could arrest tumour growth, and that ursodeoxycholic acid (UDCA) paradoxically enhanced T cell function within liver environments, fostering renewed immune cell vigour
- This presents a viable pathway for translating laboratory findings into clinical practice and could inform the development of future clinical trials designed to optimize immunotherapy by compensating for local immunosuppressive factors
- The influence of UDCA on T cell responses serves as a promising avenue for enhancing the efficacy of immunotherapy in liver cancer
- The researchers pinpointed a collection of biliary compounds that correlated with diminished T cell efficacy and heightened tumour progression
- The study catalogued the diverse bile acids present in human liver cancer biopsies, revealing an increased concentration of conjugated bile acids
- Findings indicate that optimising both the levels of beneficial bile acids and mitigating the production of harmful compounds may offer a dual strategy to reclaim immunological control over liver tumors
- The researchers discovered that certain bile acids such as lithocholic acid had detrimental effects by inducing cellular stress which hampered effective T cell responses
- Insights garnered from this study could inform the development of future clinical trials designed to optimize immunotherapy by compensating for local immunosuppressive factors
- The innovations stemming from the Salk Institute’s research indicate a critical juncture in liver cancer treatment
Read Full Article
2 Likes
For uninterrupted reading, download the app